semaglutide news october 20 2025 ACC 2025: Oral Reduces Cardiovascular Events by 14% at 4 Years Semaglutide: The Drug of Today

However, it should not be used in patients with type 1 diabetes or for treatment of diabetic ketoacidosis, and should not be coadministered with other GLP-1 receptor agonists or semaglutide-containing products

This isn't just for your safety and success

Taper / maintenance (roughly weeks 5-8+): the same per-dose amount is documented at a reduced frequency commonly 3-5 times per week rather than daily as the tissue moves from acute repair into remodeling

Injection site reactions may occur if the medication is stored at the incorrect temperature, improper injection technique is used, if alcohol residue from the swab is present, or if the person experiences body sensitivity

Using biomarker and genetic context before starting GLP-1 therapy supports a collaborative conversation with your provider about mental health monitoring, dose adjustments, and co-support strategies

Semaglutide does not show up on routine lab panels